S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Deal for UBS to buy Credit Suisse sends shares tumbling
Urgent Warning (Ad)
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Gunmen kill 9 Chinese at mine in Central African Republic
Urgent Warning (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Scottish independence at crossroads in testy SNP leader race
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Deal for UBS to buy Credit Suisse sends shares tumbling
Urgent Warning (Ad)
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Gunmen kill 9 Chinese at mine in Central African Republic
Urgent Warning (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Scottish independence at crossroads in testy SNP leader race
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Deal for UBS to buy Credit Suisse sends shares tumbling
Urgent Warning (Ad)
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Gunmen kill 9 Chinese at mine in Central African Republic
Urgent Warning (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Scottish independence at crossroads in testy SNP leader race
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Deal for UBS to buy Credit Suisse sends shares tumbling
Urgent Warning (Ad)
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Gunmen kill 9 Chinese at mine in Central African Republic
Urgent Warning (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
Scottish independence at crossroads in testy SNP leader race
Urgent Warning (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
NASDAQ:ADXN

Addex Therapeutics - ADXN Stock Forecast, Price & News

$1.10
-0.12 (-9.47%)
(As of 03/17/2023 08:53 PM ET)
Add
Compare
Today's Range
$1.07
$1.21
50-Day Range
$0.70
$2.19
52-Week Range
$0.55
$5.45
Volume
79,900 shs
Average Volume
370,177 shs
Market Capitalization
$14.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Addex Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,263.6% Upside
$15.00 Price Target
Short Interest
Healthy
2.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

848th out of 983 stocks

Pharmaceutical Preparations Industry

408th out of 480 stocks


ADXN stock logo

About Addex Therapeutics (NASDAQ:ADXN) Stock

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADXN Stock News Headlines

ADXN Addex Therapeutics Ltd
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Addex Therapeutics: Addex Regains Nasdaq Listing Compliance
Addex Regains Nasdaq Listing Compliance
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Addex Completes $4.2 Million Equity Financing
Addex Raises $4.2 million in Equity Financing
Addex Completes Reduction in Nominal Value of Shares
Why Shares Of Addex Therapeutics Are Falling Today
See More Headlines
Receive ADXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADXN Company Calendar

Last Earnings
11/04/2021
Today
3/20/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADXN
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+1,263.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,800,000.00
Net Margins
-1,737.41%
Pretax Margin
-1,737.49%

Debt

Sales & Book Value

Annual Sales
$1.23 million
Book Value
$2.26 per share

Miscellaneous

Free Float
10,929,000
Market Cap
$14.14 million
Optionable
Not Optionable
Beta
1.89

Key Executives

  • Mr. Timothy Mark Dyer (Age 54)
    Co-Founder, CEO & Director
  • Dr. Roger G. Mills M.D. (Age 65)
    Chief Medical Officer & Director
  • Mr. Lénaic Teyssédou (Age 36)
    Head of Fin.
  • Dr. Jean-Philippe Rocher Ph.D. (Age 63)
    Head of Discovery - Chemistry
  • Dr. Robert Lutjens (Age 54)
    Head of Discovery - Biology
  • Dr. Mikhail Kalinichev Ph.D. (Age 54)
    Head of Translational Science
  • Dr. Werner Henrichi Ph.D. (Age 79)
    Consultant













ADXN Stock - Frequently Asked Questions

Should I buy or sell Addex Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Addex Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXN, but not buy additional shares or sell existing shares.
View ADXN analyst ratings
or view top-rated stocks.

What is Addex Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month target prices for Addex Therapeutics' stock. Their ADXN share price forecasts range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,263.6% from the stock's current price.
View analysts price targets for ADXN
or view top-rated stocks among Wall Street analysts.

How have ADXN shares performed in 2023?

Addex Therapeutics' stock was trading at $0.6301 at the beginning of 2023. Since then, ADXN stock has increased by 74.6% and is now trading at $1.10.
View the best growth stocks for 2023 here
.

Are investors shorting Addex Therapeutics?

Addex Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 338,700 shares, an increase of 149.8% from the February 13th total of 135,600 shares. Based on an average daily volume of 304,500 shares, the short-interest ratio is presently 1.1 days.
View Addex Therapeutics' Short Interest
.

When is Addex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ADXN earnings forecast
.

How were Addex Therapeutics' earnings last quarter?

Addex Therapeutics Ltd (NASDAQ:ADXN) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, hitting analysts' consensus estimates of ($0.72). The firm had revenue of $0.83 million for the quarter, compared to analyst estimates of $0.42 million. Addex Therapeutics had a negative net margin of 1,737.41% and a negative trailing twelve-month return on equity of 190.82%. During the same quarter in the previous year, the business posted ($0.78) earnings per share.

What other stocks do shareholders of Addex Therapeutics own?
What is Addex Therapeutics' stock symbol?

Addex Therapeutics trades on the NASDAQ under the ticker symbol "ADXN."

Who are Addex Therapeutics' major shareholders?

Addex Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (8.40%) and Susquehanna International Group LLP (0.56%).

How do I buy shares of Addex Therapeutics?

Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Addex Therapeutics' stock price today?

One share of ADXN stock can currently be purchased for approximately $1.10.

How much money does Addex Therapeutics make?

Addex Therapeutics (NASDAQ:ADXN) has a market capitalization of $14.14 million and generates $1.23 million in revenue each year. The company earns $-16,800,000.00 in net income (profit) each year or ($3.54) on an earnings per share basis.

How can I contact Addex Therapeutics?

Addex Therapeutics' mailing address is CHEMIN DES AULX 12 PLAN-LES-OUATES, GENEVA V8, CH-1228. The official website for the company is www.addextherapeutics.com. The company can be reached via phone at 011-41-22-884-1555, via email at investor.relations@addextherapeutics.com, or via fax at 41-22-884-1556.

This page (NASDAQ:ADXN) was last updated on 3/20/2023 by MarketBeat.com Staff